NIH Phase 1 Exploratory/Developmental Grant (R61)
Funds Phase 1 Exploratory/Developmental Grant, NIH's R61 mechanism.
The National Institutes of Health describes the Phase 1 Exploratory/Developmental Grant (R61) this way: As part of a bi-phasic approach to funding exploratory and/or developmental research, the R61 provides support for the first phase of the award. This activity code is used in lieu of the R21 activity code when larger budgets and/or project periods are required to establish feasibility for the pr…
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.
Funds early-stage clinical trials in arthritis, musculoskeletal and skin disease. A trial is compulsory.
Funds the discovery and first evaluation of biomarkers for neurological and neuromuscular disorders, ending with candidates ready for formal validation.
Funds Phase I trials for heart, lung, blood and sleep disorders — and pays for the final preclinical work needed to start one.
Funds a therapeutic or diagnostic device for the nervous system through prototyping, safety testing, regulatory clearance and a first small clinical study.
Funds building the assays and running the screens that find drug candidates for neurological disease — the on-ramp to NIH's Blueprint network.
Funds building animal and tissue models that behave enough like a real neurological disease to test drugs against.
Funds two years establishing that a psychosocial intervention hits its target, then three replicating it and linking it to clinical change.
Funds a feasibility phase then a testing phase for a novel-mechanism drug or a device for mental disorders, with milestones between them.
Funds two years finding the host biology behind inconsistent probiotic responses, then more to test whether those patterns actually predict who responds.
Funds the pharmacology and animal efficacy work that shows a neurological drug candidate is worth developing further.
Funds three years of pharmacokinetics and target-engagement work on a botanical, probiotic or supplement, then three more if the milestones are met.
Funds a feasibility and infrastructure phase, then a well-powered trial, of an intervention aimed at how mental health services are organised and delivered.
Funds mechanistic trials testing how mind-body practices change emotional well-being, in two gated phases.
Funds a single-site clinical trial in heart, lung or blood disease, run through two milestone-gated phases by one team.
Funds proof-of-concept work on a genuinely new tool, assay, platform or instrument for characterising cancer cells or handling biospecimens.
Funds early proof-of-concept work testing whether a new cancer research tool, assay, platform or instrument is technically feasible at all.
Funds action-oriented research turning addiction prevention, treatment and recovery science into real-world practice.
Funds exploratory human studies that record and stimulate neurons directly, using brain access that invasive procedures already create.
Funds identifying and validating a disease target, then finding a preliminary drug, biologic or combination-product lead against it.
Funds building and testing an early medical-device prototype and its matching disease target or assay, for heart, lung, blood or sleep disease.
Funds the assays, screening and first characterisation that a pain drug discovery programme needs before it can start properly.
Funds planning then running a milestone-driven clinical trial for a health condition that co-occurs with Down syndrome.